-
55m 59s
-
50m 10s
-
2m 50sPart 7 Close and Key Takeaways
-
3m 45sPart 1 Welcome and Introduction
-
57m 27s
New Horizons in Cardio Kidney Disease, is a new one-day virtual educational event that took place live on 30 June 2026, designed to address current challenges in cardio-kidney care through practical, cross-disciplinary education, with a focus on biomarker-guided risk assessment, optimisation of blood pressure and cardio-kidney therapies, and emerging multimodal strategies.
Led by course directors Dr Muthiah Vaduganathan (Brigham and Women's Hospital, Boston, US), Dr Neha Pagidipati (Duke Clinical Research Institute, Durham, US), and Prof Smeeta Sinha (Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK), the programme features expert-led presentations, case-based discussions, and multidisciplinary panel sessions. This interactive, collaborative format reflects real-world care pathways and supports the wider implementation of evidence-based strategies in clinical practice.
Watch the full on-demand series* to stay at the forefront of cardio-kidney disease management and enhance your practice with the latest clinical insights.
*Please note, the live version of New Horizons in Cardio Kidney Disease was accredited. This on-demand version is not.
The symposium 'Clinical Utility of eGFR Slope Across Cardio-Kidney Care and Trial Design' is also available to watch here (This session is not intended for UK based HCPs).
Key Learning Objectives
- Increase confidence interpreting albuminuria and integrating biomarkers into risk models
- Improve confidence interpreting BP phenotypes and organ-injury signals to inform escalation decisions
- Improve understanding of therapy sequencing and combination approaches
- Greater adoption of multidisciplinary care pathways
- Enhance readiness for emerging multimodal strategies
Target Audience
- Cardiologists
- Nephrologists
- Primary Care Physicians
- Diabetes Specialists
- Endocrinologists
More from this programme
Part 1
New Horizons in Cardio Kidney Disease: Welcome and Introduction
Neha Pagidipati (Durham, US) and Smeeta Sinha (Salford, UK) introduce the programme and share the key learning objectives.
| 1 session | |
| Welcome and Introduction | Watch now |
Part 2
Session 1: Defining Persistent Risk in Cardio Kidney Disease
Neha Pagidipati (Durham, US) chairs the first session, where faculty focus on defining persistent risk in cardio-kidney disease and exploring the mechanisms that have the greatest relevance for clinical practice. She is joined by Katherine Tuttle (Seattle, US), Erika Jones (Cape Town, SA) and Shelley Zieroth (Winnipeg, CA) for presentations and panel discussion.
Part 3
Session 2: Biomarkers That Guide Decisions
Smeeta Sinha (Salford, UK) chairs this session which demonstrates how biomarkers can identify high-risk patients earlier and enable more informed treatment decisions. She is joined by Navdeep Tangri (Winnipeg, CA), Neha Pagidipati (Durham, US) and Alta Schutte (Sydney, AU) for presentations and panel discussion.
Part 4
Session 3: Optimising Care, From Guidelines to Practice
Muthiah Vaduganathan (Boston, US) chairs this session, which translates risk identification into risk reduction by exploring therapeutic classes and strategies within the context of guideline-directed care, residual risk, and multimodal protection. He is joined by Biykem Bozkurt (Houston, US), Anjay Rastogi (Los Angeles, US) and Hiddo J L Heerspink (Groningen, NL) for presentations and panel discussion.
Part 5
Session 4: Coordinating Multidisciplinary Cardio Kidney Risk Management
Neha Pagidipati (Durham, US) chairs this session and is joined by Anjay Rastogi (Los Angeles, US), Muthiah Vaduganathan (Boston, US) and Smeeta Sinha (Salford, UK). The session explores how multidisciplinary care can improve outcomes.
Part 6
Session 5: Case-Based Decisions Translation
Muthiah Vaduganathan (Boston, US) chairs the final session, a case-based panel discussion that brings together key themes from the previous sessions. A global multidisciplinary panel featuring Jeff Borenstein (Los Angeles, US), Biykem Bozkurt (Houston, US), Erika Jones (Cape Town, SA), Nicholas Jones (Oxford, UK) and Katherine Tuttle (Seattle, US) share their perspectives.
The panel review a case of a 72-year-old male patient. Beyond the case discussion, the panel explore applying biomarker findings to real-world decision-making, navigating therapy sequencing in patients with residual cardio-kidney risk, and identifying multidisciplinary decision points across cardiology, nephrology, and primary care.
Part 7
New Horizons in Cardio Kidney Disease: Close and Key Takeaways
Muthiah Vaduganathan (Boston, US) brings New Horizons in Cardio Kidney Disease 2026 to a close, sharing key insights and takeaways from the day.
| 1 session | |
| Close and Key Takeaways | Watch now |
Faculty Biographies
Smeeta Sinha
Consultant Nephrologist
Prof Smeeta Sinha is Consultant Nephrologist at the Northern Care Alliance NHS Foundation Trust and Honorary Professor at the University of Manchester, UK. She served as Clinical Director for Renal Services from 2014 to 2020, expanding kidney care across Greater Manchester. In 2021, she became Deputy Director for Research & Innovation at Northern Care Alliance.
Her clinical interests include CKD, metabolic stone disease and glomerulonephritis. She leads the integrated glomerulonephritis service at Salford Royal, covering 1.3 million people.
Her research focuses on CKD-mineral bone disorder, vascular calcification, glomerulonephritis and rare renal diseases. She is an internationally recognised expert in calciphylaxis and supports trials from Phase 1 to 3.
Navdeep Tangri
Professor of Medicine in the Division of Nephrology
Dr Navdeep Tangri is a Professor of Medicine in the Division of Nephrology at University of Manitoba, Winnipeg, CA.
Dr Tangri's research programme is focused on the clinical management of patients with advanced chronic kidney disease. He developed the kidney failure risk equation (KFRE) to predict the need for dialysis in patients with chronic kidney disease.
Neha Pagidipati
Assistant Professor of Medicine
Neha J Pagidipati is an Assistant Professor of Medicine and cardiovascular disease prevention specialist. Since 2011, she has conducted research on cardiometabolic disease prevention, lifestyle modification and weight management. She is currently an NIH K12 scholar in Implementation and Dissemination Science.
Dr Pagidipati is building the Duke Cardiometabolic Disease Prevention Program, which focuses on behavior change and risk factor management in patients with high risk of cardiovascular and metabolic diseases such as diabetes and obesity.
Dr Pagidipati’s research grants include the COORDINATE-Diabetes Trial, to improve the quality of care for patients with diabetes and cardiovascular disease across the US, and QuBBD: Deep Poisson Methods for Biomedical Time-to-Event and Longitudinal Data.
In addition, she is leading a large study within the Duke Health System to study heterogeneity within cardiovascular disease risk and…
Alta Schutte
Faculty of Medicine and Health at UNSW Sydney, Australia
Prof Alta Schutte is a Professor and Principal Theme Lead of Cardiac, Vascular and Metabolic Medicine in the Faculty of Medicine and Health at UNSW Sydney, Australia; with a joint appointment as Professorial Fellow at the George Institute for Global Health. Prof Schutte has extensive experience in working in clinical and population-based studies with a focus on raised blood pressure, hypertension and cardiovascular disease. She is involved in numerous international consortia, such as the Global Burden of Disease study, the NCD Risk Factor Collaboration and the May Measurement Month initiative of the International Society of Hypertension. Her expertise includes the management of hypertension and monitoring of raised blood pressure, actions and interventions to improve blood pressure control and the detection, treatment and control of hypertension.